Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer
This is a Phase 1 open-label study evaluating the safety of ABT-263 when combined with a standard and weekly regimen of docetaxel in subjects who have solid tumors with measurable disease.
Solid Tumor
DRUG: ABT-263|DRUG: Docetaxel
Assess the safety profile of navitoclax (ABT-263) when administered in combination with a standard and weekly regimen of docetaxel., Weekly|Study the pharmacokinetic interaction of navitoclax (ABT-263) and docetaxel, Weekly|Determine the maximum tolerated dose (MTD) of navitoclax (ABT-263) with a standard regimen of docetaxel, Weekly|Determine the MTD of both navitoclax and docetaxel with a weekly schedule., Weekly
Evaluate safety at the defined recommended Phase 2 dose (RPTD) and schedule in combination with a standard and weekly regimen of docetaxel., Bimonthly|Evaluate preliminary data regarding progression free survival, Bimonthly|Evaluate preliminary data regarding objective response rate, Bimonthly|Evaluate preliminary data regarding overall survival, Bimonthly|Evaluate preliminary data regarding duration of overall response, Bimonthly|Evaluate preliminary data with Eastern Cooperative Oncology Group (ECOG) performance status, Bimonthly|Evaluate biomarkers, Define the relationship between disease states, B-Cell Lymphoma 2 (Bcl-2) family protein expression, and potential response to the proposed therapy navitoclax when added to a standard and weekly regimen of docetaxel., Bimonthly
This is a Phase 1 open-label study evaluating the safety of ABT-263 when combined with a standard and weekly regimen of docetaxel in subjects who have solid tumors with measurable disease.